Advancements in Genomic Technologies and Rising Demand for Personalized Medicine Drive Growth in the Global Metabolomics Biomarker Market

The metabolomics biomarker market was valued at $415.8 million in 2024 and is projected to reach $1,651.6 million by 2035, growing at a CAGR of 13.4% during the forecast period (2025–2035). The growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer is driving demand for metabolomics biomarkers, which enable early diagnosis, disease monitoring, and personalized treatment strategies. Increasing focus on precision medicine is further accelerating adoption across clinical and research settings.

Browse the full report description of “Metabolomics Biomarker Market Size, Share & Trends Analysis Report By Application (Biomarker Discovery, Drug Discovery and Assessment, Toxicology Testing, Functional Genomics, Nutrigenomics, And Personalized Medicine.), By Technology (Chromatography, Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR) Spectroscopy, and Bioinformatics Tools & Services), By Organization Size (Large Enterprises and Small & Medium-Sized Enterprises (SMES)), and By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROS), and Diagnostic Laboratories), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/metabolomics-biomarker-market

At the same time, advancements in genomic and metabolomic technologies, including high-throughput mass spectrometry and bioinformatics platforms, are improving analytical accuracy and reducing testing costs. These innovations, combined with supportive research initiatives and collaborations, are fostering wider application of metabolomics biomarkers globally.

Real-Life Developments Highlight the Growing Importance of Metabolomics Biomarkers

• 2025: A study by the National Institutes of Health (NIH) highlighted that integrating metabolomics with genomic and proteomic data improved precision medicine approaches, enabling more effective therapeutic interventions.
• 2024: The World Health Organization (WHO) reported a rising global prevalence of chronic diseases, emphasizing the need for metabolomics biomarkers to support early diagnosis, disease monitoring, and personalized treatment strategies.
• 2025: Collaborations between pharmaceutical companies, diagnostic labs, and research institutions accelerated the development and commercialization of metabolomics biomarkers, supporting drug development and personalized healthcare globally.

Innovation and Strategic Adoption in the Metabolomics Biomarker Market

Industry players are investing in advanced metabolomic platforms, high-throughput analytical technologies, and bioinformatics tools to enhance accuracy and scalability of biomarker testing. Companies are also collaborating with pharmaceutical firms and research institutions to support personalized medicine initiatives, accelerate clinical adoption, and expand global market reach.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Application
• Technology
• End-User

• Competitive Landscape – Agilent Technologies, Bio-Rad Laboratories, Bruker Corp., Danaher Corp. and Thermo Fisher Scientific.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Metabolomics Biomarker Market Report Segment

By Application

• Biomarker Discovery
• Drug Discovery and Assessment
• Toxicology Technology
• Functional Genomics
• Nutrigenomics
• Personalized Medicine

By Technology

• Chromatography
• Mass Spectrometry (MS)
• Nuclear Magnetic Resonance (NMR) Spectroscopy
• Bioinformatics Tools & Services

By End-User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)
• Diagnostic Laboratories

Global Metabolomics Biomarker Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/metabolomics-biomarker-market